Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.
Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.